Exelixis Inc reports results for the quarter ended March 31 - Earnings Summary
13/05/2025 22:01
Exelixis Inc EXEL.OQ reported quarterly adjusted earnings of 55 cents per share for the quarter ended March 31, higher than the same quarter last year, when the company reported EPS of 20 cents. The mean expectation of eighteen analysts for the quarter was for earnings of 36 cents per share. Wall Street expected results to range from 19 cents to 50 cents per share. Revenue rose 30.6% to $555.45 million from a year ago; analysts expected $498.18 million. Exelixis Inc's reported EPS for the quarter was 55 cents. The company reported quarterly net income of $159.62 million. Exelixis Inc shares had risen by 0.2% this quarter and gained 11.1% so far this year. FORECAST CHANGES The mean earnings estimate of analysts had fallen by about 3.3% in the last three months. In the last 30 days, one analyst negatively revised an earnings estimate RECOMMENDATIONS The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 11 "strong buy" or "buy," 9 "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy" Wall Street's median 12-month price target for Exelixis Inc is $39.00 This summary was machine generated from LSEG data May 13 at 09:01 p.m. UTC. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
| QUARTER ENDING | ESTIMATE | ACTUAL | BEAT, MET, MISSED |
| Mar. 31 2025 | 0.36 | 0.55 | Beat |
| Dec. 31 2024 | 0.43 | 0.48 | Beat |
| Sep. 30 2024 | 0.35 | 0.40 | Beat |
| Jun. 30 2024 | 0.30 | 0.77 | Beat |